Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Retrovirus Life Cycles01:10

Retrovirus Life Cycles

Retroviruses have a single-stranded RNA genome that undergoes a special form of replication. Once the retrovirus has entered the host cell, an enzyme called reverse transcriptase synthesizes double-stranded DNA from the retroviral RNA genome. This DNA copy of the genome is then integrated into the host’s genome inside the nucleus via an enzyme called integrase. Consequently, the retroviral genome is transcribed into RNA whenever the host’s genome is transcribed, allowing the retrovirus to...
Drug Therapy01:28

Drug Therapy

The advent of drug therapy has profoundly shaped modern mental health care, providing targeted treatments for a range of psychological disorders. Psychotherapeutic drugs, classified into antianxiety, antidepressant, and antipsychotic medications, address symptoms across anxiety disorders, mood disorders, and schizophrenia. While these medications have transformed patient outcomes, they require careful management due to their potential side effects and limitations.
Antianxiety Medications
Hepatitis01:25

Hepatitis

Hepatitis is an inflammatory condition of the liver most commonly caused by hepatotropic viruses (A–E), though non-infectious causes such as alcohol and drugs also exist.Hepatitis AHepatitis A virus (HAV) is a non-enveloped RNA virus of the Picornaviridae family. It is primarily transmitted via the fecal-oral route, typically through ingestion of contaminated food or water. After ingestion, HAV enters the bloodstream through the oropharynx or intestinal epithelium and reaches the liver. The...
Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Antiviral Nucleoside Inhibitors01:22

Antiviral Nucleoside Inhibitors

Antiviral Nucleoside InhibitorsAntiviral nucleoside inhibitors are structural analogs of natural nucleosides that interfere with viral DNA or RNA synthesis. These compounds selectively target viral polymerases due to their resemblance to host nucleosides, thereby disrupting viral genome replication.Mechanism of Acyclovir ActionAcyclovir is a guanosine analog with a three-carbon acyclic side chain. It selectively targets herpes simplex virus type 1 (HSV-1), herpes simplex virus type 2 (HSV-2),...
Viral Hepatitis I: Introduction01:28

Viral Hepatitis I: Introduction

Viral hepatitis is an inflammatory condition of the liver caused by infection with hepatotropic viruses, most commonly hepatitis A, B, C, D, and E. Despite variations in structure and transmission, all viruses mentioned infect hepatocytes and provoke immune responses that can hinder liver function. Additionally, some non-hepatotropic viruses can also lead to hepatic inflammation.Hepatitis A VirusHepatitis A virus (HAV) is transmitted through the fecal–oral route, typically by ingestion of food...

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

European survey on the current surveillance practices, management guidelines, treatment pathways and heterogeneity of testing of Clostridioides difficile, 2018-2019: results from The Combatting Bacterial Resistance in Europe CDI (COMBACTE-CDI).

The Journal of hospital infection·2022
Same author

Alisporivir with peginterferon/ribavirin in patients with chronic hepatitis C genotype 1 infection who failed to respond to or relapsed after prior interferon-based therapy: FUNDAMENTAL, a Phase II trial.

Journal of viral hepatitis·2014
Same author

Limiting hepatitis C virus progression in liver transplant recipients using sirolimus-based immunosuppression.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

High mean fluorescence intensity donor-specific anti-HLA antibodies associated with chronic rejection Postliver transplant.

American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons·2011
Same author

Radium content of ultramafic igneous rocks; laboratory investigation.

American journal of science·2010
Same author

Planning the hospital for community service.

Minnesota medicine·2010
Same journal

How important is fiber in the Crohn's disease story?

Gastroenterology·2026
Same journal

Reply to "Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy".

Gastroenterology·2026
Same journal

Critical Appraisal of the Integrin αV-YAP-CTGF Axis in Congestive Hepatopathy.

Gastroenterology·2026
Same journal

A High-Risk Impaction: To Scope or to Stent First?

Gastroenterology·2026
Same journal

Epithelial FOXP3 orchestrates O-glycosylated IL-6 secretion to drive pancreatic fibrocarcinogenesis.

Gastroenterology·2026
Same journal

Reply to "Methodological Considerations on Neonatal Metabolomics and Future Inflammatory Bowel Disease".

Gastroenterology·2026
See all related articles

Related Experiment Video

Updated: Jun 25, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Current therapy for chronic hepatitis C.

G L Davis1

  • 1Department of Medicine, University of Florida College of Medicine, Gainesville 32610-0214, USA.

Gastroenterology
|June 27, 2000
PubMed
Summary
This summary is machine-generated.

Chronic hepatitis C virus infection affects millions, often leading to cirrhosis and liver transplant needs. Combination therapy with interferon and ribavirin offers improved sustained virological response rates.

More Related Videos

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Related Experiment Videos

Last Updated: Jun 25, 2026

A Protocol for Analyzing Hepatitis C Virus Replication
13:04

A Protocol for Analyzing Hepatitis C Virus Replication

Published on: June 26, 2014

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice
07:25

Stem Cell-Derived Viral Ag-Specific T Lymphocytes Suppress HBV Replication in Mice

Published on: September 25, 2019

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target
11:34

A Competent Hepatocyte Model Examining Hepatitis B Virus Entry through Sodium Taurocholate Cotransporting Polypeptide as a Therapeutic Target

Published on: May 10, 2022

Area of Science:

  • Hepatology
  • Virology
  • Immunology

Background:

  • Chronic hepatitis C virus (HCV) infection is a significant public health concern in the US, affecting an estimated 2.7 million individuals.
  • Long-standing HCV infections, particularly those acquired over 20 years ago, are increasingly leading to decompensated cirrhosis and liver transplantation.
  • HCV-induced cirrhosis is now the primary indication for liver transplantation.

Purpose of the Study:

  • To evaluate the efficacy of combination therapy for chronic hepatitis C.
  • To assess treatment outcomes in previously untreated patients and those who relapsed after interferon monotherapy.
  • To explore the potential benefit of retreatment in non-responders.

Main Methods:

  • Review of clinical data on interferon monotherapy and combination therapy with ribavirin.
  • Analysis of sustained virological response rates in different patient groups.
  • Examination of factors influencing treatment response, including prior treatment history and viral characteristics.

Main Results:

  • Interferon monotherapy achieved sustained virological response in less than 10% of patients.
  • Combination therapy with interferon and ribavirin for 6-12 months yields sustained virological response in 30%-40% of previously untreated patients.
  • Combination therapy shows excellent response rates in patients who relapsed after interferon monotherapy and may benefit a subset of non-responders.

Conclusions:

  • Combination therapy significantly improves sustained virological response rates compared to interferon monotherapy for chronic hepatitis C.
  • Interferon and ribavirin combination therapy is a valuable treatment option for both naive and relapsed HCV patients.
  • Further investigation into retreatment strategies for non-responders is warranted.